• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-X filed by Profound Medical Corp.

    6/14/24 5:23:52 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care
    Get the next $PROF alert in real time by email
    F-X 1 tm2417174d3_fx.htm F-X

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    FORM F-X

     

    Appointment of Agent For Service of Process
    And Undertaking

     

    A. Name of issuer or person filing (the “Filer”):   Profound Medical Corp.

     

    B. (1) This is (check one):

     

    x  an original filing for the Filer

     

    ¨   an amended filing for the Filer

     

          (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9) ¨

     

    C. Identify the filing in conjunction with which this form is being filed:

     

          Name of Registrant:   Profound Medical Corp.
         
          Form Type:   Registration Statement on Form F-10
         
          File Number (if known):   333-280236
         
          Filed by:   Profound Medical Corp.
         
          Date Filed (if filed concurrently, so indicate):   June 14, 2024 (filed concurrently)

     

    D. Filer is incorporated or organized under the laws of Ontario, Canada and has its principal place of business at:

     

    2400 Skymark Avenue,

    Unit 6,

    Mississauga, Ontario, Canada

    L4W 5K5

    (telephone: (647) 476-1350).

     

    E. The Filer designates and appoints Profound Medical (U.S.) Inc. (the “Agent”), located at

     

    9160 Forum Corporate Parkway,

    Suite 359

    Fort Myers, FL

    33905

    (telephone: (647) 476-1350)

    Attention: Arun Menawat

     

    as the agent of the Filer upon whom may be served any process, pleadings, subpoenas, or other papers in:

     

    (a) any investigation or administrative proceeding conducted by the Commission; and

     

    (b) any civil suit or action brought against the Filer or to which the Filer has been joined as defendant or respondent, in any appropriate court in any place subject to the jurisdiction of any state or of the United States or of any of its territories or possessions or of the District of Columbia, where the investigation, proceeding or cause of action arises out of or relates to or concerns any offering made or purported to be made in connection with the securities registered or qualified by the Filer on Form F-10 on the date hereof (the “Form F-10”) or any purchases or sales of any security in connection therewith. The Filer stipulates and agrees that any such civil suit or action or administrative proceeding may be commenced by the service of process upon, and that service of an administrative subpoena shall be effected by service upon such agent for service of process, and that the service as aforesaid shall be taken and held in all courts and administrative tribunals to be valid and binding as if personal service thereof had been made.

     

      F. The Filer stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date the issuer of the securities to which such forms and schedules relate has ceased reporting under the Exchange Act.

     

    The Filer further undertakes to advise the Commission promptly of any change to the Agent’s name or address during the applicable period by amendment of this form, referencing the file number of the relevant form in conjunction with which the amendment is being filed.

     

      G. The Filer undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to the Form F-10; the securities to which the Form F-10 relates; and the transactions in such securities.

     

     

     

     

     

     

    The Filer certifies that it has duly caused this power of attorney, consent, stipulation and agreement to be signed on its behalf by the undersigned, thereto duly authorized, in the City of Mississauga, Province of Ontario, Country of Canada, on June 14, 2024.

     

    Filer: PROFOUND MEDICAL CORP.  
           
           
      By: /s/ Rashed Dewan  
        Name: Rashed Dewan  
        Title: Chief Financial Officer  

     

    This statement has been signed by the following person in the capacity and on the date indicated:

     

    PROFOUND MEDICAL (U.S.) INC.  
       
    as U.S. agent for service of process  
         
    By: /s/ Arun Menawat  
      Name: Arun Menawat  
      Title: Chief Executive Officer  

     

    Dated: June 14, 2024

     

     

    Get the next $PROF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PROF

    DatePrice TargetRatingAnalyst
    7/23/2024$16.50Buy
    Lake Street
    7/16/2024$9.00 → $12.00Hold → Buy
    Stifel
    11/28/2023$11.00Hold
    Stifel
    8/4/2023$20.00 → $200.00Strong Buy → Outperform
    Raymond James
    3/21/2023$5.50 → $10.00Buy → Hold
    Jefferies
    3/7/2022$28.00 → $14.00Outperform
    Cowen & Co.
    2/22/2022$28.00 → $23.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $PROF
    SEC Filings

    View All

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    2/5/26 8:05:28 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    1/27/26 6:17:25 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    1/15/26 7:35:27 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Profound Medical with a new price target

    Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50

    7/23/24 8:51:59 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical upgraded by Stifel with a new price target

    Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously

    7/16/24 7:45:31 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Profound Medical with a new price target

    Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00

    11/28/23 7:53:24 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women's Health

    TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve® Procedure. The MRI-guided therapy provides women with a non-surgical alternative for treating common gynecologic conditions—delivering targeted relief with no incisions, no blood loss during the procedure, no overnight hospital stay, and a faster recovery. "Sonalleve is giving more women access to a safer, gentler a

    2/5/26 8:00:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Announces Upcoming Investor Events

    TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February. Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4th-5th in Scottsdale, AZ.BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference: The Company is scheduled to participate in a series of one-on-one meetings February 10th-11th in Snowbir

    1/27/26 4:30:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®

    Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce the world-renowned Mount Sinai Hospital has successfully treated its first prostate cancer patient with the TULSA-PRO® system. The TULSA Procedure™ represents a major advancement in pr

    1/15/26 7:30:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Leadership Updates

    Live Leadership Updates

    View All

    Profound Medical Annual General and Special Meeting of Shareholders Voting Results

    TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 4, 2025 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders

    5/14/25 4:45:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

    – Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t

    10/16/24 4:15:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Annual General Meeting of Shareholders Voting Results

    TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp

    5/15/24 5:00:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Financials

    Live finance-specific insights

    View All

    Profound Medical Reports Strong Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).   Business Highlights Revenue grew 87% year-over-year to a record $5.3 million in the third quarter of 2025.Gross margin increased 1,119 basis p

    11/13/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

    TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the third quarter of 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars. For the quarter ended September 30, 2025, Profound anticipates total revenues to be in the approximate range of $5.2 million to $5.3 million, representing revenue growth of between 84% and 87% over $2.8 million in the same three-month period a year ag

    10/7/25 7:45:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Announces Second Quarter 2025 Financial Results

    TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Utilization of current TULSA-PRO® systems continues to grow, with "same store" procedure volumes up 10% sequentially from Q1-2

    8/14/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    11/14/24 4:27:34 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    8/5/24 7:50:30 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    3/13/24 4:00:16 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care